Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-

DB16204InvestigationalSmall molecule

Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis).

Formula / weight: C₂₃H₂₁F₃N₂ · 382.43 g/mol (avg)
Code names: SSR-150106 · SSR-150106XB

Resolves to

Compound

UNII5WX0OAF07ICAS335267-09-9ChEMBLCHEMBL4297498

Structure

InChIKeyZXXHOPNSTZKWRI-UHFFFAOYSA-NSMILESFC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC3=C(C=CN=C3)C=C2)CC1

What you can answer from here — as of December 20, 2020

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account